MEMOPTIC

PreclinicalSmall molecule

CCentre Hospitalier Universitaire, Amiens

MEMOPTIC is one of 12 small molecule programs targeting Open-Angle Glaucoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Open-Angle GlaucomaActive, not recruiting

Open-Angle GlaucomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Open-Angle Glaucoma

#DrugCompanyPhaseTrials

Zolymbus

AbbVie

Approved

1 2

Ozempic

Novo Nordisk

Approved

1 3

Travatan

Namenda

Xalatan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 6

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Adrucil

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Isopto Carpine

Mitosol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Open-Angle Glaucoma1 trial

Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma

Unknown status·—·N/A·NCT04499157·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MEMOPTIC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MEMOPTIC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MEMOPTIC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Hospitalier Universitaire, Amiens company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCentre Hospitalier Universitaire, Amiens

MEMOPTIC

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Open-Angle Glaucoma1 trial

References

Drug Info

Quick Facts

Related News